S&P 500 Falls 2.5% Amid Geopolitical Concerns
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 04 2026
0mins
S&P 500 succumbed to another day of heavy selling amid geopolitical concerns on Tuesday, falling as much as 2.5% at one point, as fears of a protracted Middle East conflict that drew in multiple regional players roiled sentiment. Stocks recovered from the opening hour lows however as traders bought the beaten down Software Application names while also hiding out in the safety of high-yielding Telecoms. The opening hour of the evening session is seeing a calmer mood with equity futures down by only a decimal, even though investors remain on high alert for another "tape bomb" in a headline-driven volatile macro environment.In commodities, Gold and Silver were down sharply, refusing to act as stores of refuge, with a second consecutive session of much stronger U.S. Dollar denting precious metals. WTI Crude Oil is flat in electronic trade in the wake of a large build in inventories reported by API, having retreated below $74.50 after rising as high as $78 per barrel earlier.Check out this evening's top movers from around Wall Street, compiled by The Fly.HIGHER AFTER EARNINGS -Evolusup 17.4%B&G Foodsup 7.7%Ross Storesup 6.1%Boxup 3.5%Cricutup 2.8%ALSO HIGHER -Modernaup 8.0% after announcing litigation settlementDOWN AFTER EARNINGS -WEBTOON Entertainmentdown 14.3%GitLabdown 8.9%STAAR Surgicaldown 8.9%QuickLogicdown 3.7%Crexendodown 2.3%Crowdstrikedown 0.7%
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy EOLS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on EOLS
Wall Street analysts forecast EOLS stock price to rise
5 Analyst Rating
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 6.570
Low
18.00
Averages
19.25
High
20.00
Current: 6.570
Low
18.00
Averages
19.25
High
20.00
About EOLS
Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins and injectable hyaluronic acid gels. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and certain European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Conexeu Sciences Inc. Begins Trading on Nasdaq
- Listing Milestone: Conexeu Sciences Inc. commenced trading on Nasdaq on May 21, 2026, marking a significant advancement for the preclinical-stage company centered around its CXU™ bioregenerative platform, which is expected to attract more investment for product development.
- Innovative Platform: The CXU™ is a patented bioregenerative extracellular matrix designed to restore soft tissue lost due to injury, aging, and GLP-1-related weight loss, with its first product, Ten Minute Tissue™, demonstrating enhanced healing dynamics and a low inflammatory profile in preclinical studies, potentially garnering significant market interest.
- Market Outlook: Conexeu enters a public market that is showing genuine commercial momentum, with competitors like Integra LifeSciences and Bioventus exceeding expectations in recent earnings reports, indicating strong demand in the regenerative medicine sector, and the listing is likely to enhance Conexeu's market share.
- Strategic Positioning: The listing not only provides Conexeu with the opportunity for capital formation but also enables the advancement of the CXU™ platform across multiple product lines, with plans to submit a 510(k) application in early 2027, further solidifying its position in the regenerative medicine field.
See More
Conexeu Sciences Inc. Successfully Debuts on Nasdaq
- Listing Milestone: Conexeu Sciences Inc. commenced trading on Nasdaq on May 21, 2026, marking its entry into public markets as a regenerative tissue platform company, which is expected to drive business growth in wound care and aesthetic medicine sectors.
- Platform Advantage: The company's CXU™ extracellular matrix platform is designed to scale across multiple markets without reformulation, a structural advantage that sets it apart from early-stage regenerative medicine companies and may lay the groundwork for future market share expansion.
- Innovative Reconstruction Method: Conexeu's B.R.E.A.S.T.™ matrix is a 3D bioprinted scaffold designed to support the body's own tissue regeneration rather than serve as a permanent implant, representing a potential paradigm shift for over 100,000 U.S. women undergoing mastectomies annually.
- Intellectual Property Protection: Conexeu holds issued patents across the U.S., E.U., Japan, and Australia with no royalty or licensing obligations, providing the freedom to expand into new indications and potentially accelerating its 510(k) submission process.
See More
Evolus to Host Investor Meetings at Jefferies Conference
- Management Participation: Evolus's management team will participate in a fireside chat at the upcoming Jefferies Global Healthcare Conference on June 4, 2026, showcasing their expertise in aesthetics and likely attracting investor interest.
- Fireside Chat Timing: Scheduled for 12:50 PM ET, the chat will be accessible via the Investor Relations page on Evolus's website, enhancing interaction between the company and its investors.
- Webcast Replay Availability: A replay of the presentation will be available for 90 days post-event, ensuring that investors who cannot attend live can still access the information, thereby improving transparency and information dissemination.
- Company Background: Evolus is a global performance beauty company focused on redefining the aesthetic injectable market through its unique customer-centric business model and innovative digital platform, aiming to become a leader in the field.
See More
Evolus Launches Estyme® Injectable Products in Europe
- International Market Expansion: Evolus is set to commercially launch its Estyme® injectable hyaluronic acid gel collection on May 16, marking its entry into the international dermal filler market, which is expected to significantly enhance the company's market share in the global aesthetics sector.
- Product Diversity: The Estyme® collection includes Estyme®Smooth, Estyme®Form, Estyme®Lips, and Estyme®Sculpt, the latter of which is anticipated to receive FDA approval in the U.S., addressing the strong demand for mid-face volumizing treatments and enhancing the competitiveness of the company's product portfolio.
- Technological Innovation: Estyme®Sculpt utilizes Symatese's Cold-X® technology designed to preserve the natural structure of the hyaluronic acid molecule, providing long-lasting and natural-looking results, which will enhance practitioners' flexibility in treatments and patient satisfaction.
- Market Potential: The launch of Estyme® is expected to double Evolus's addressable market in the dermal filler category, supporting the company's strategic goal of becoming a global leader in multi-product aesthetics, thereby further solidifying its position in the industry.
See More
Evolus Q1 2026 Earnings Call Highlights
- Financial Performance: In Q1 2026, Evolus reported global net revenue of $73.1 million, including $66.4 million from Jeuveau and $6.7 million from Evolysse, indicating stable performance despite ongoing market challenges.
- Profitability Improvement: The company achieved positive adjusted EBITDA of $0.6 million in Q1, a significant turnaround from a loss of $5.5 million in the prior year, demonstrating progress in profitability and boosting investor confidence.
- Market Share Maintenance: Evolus maintained a 14% market share in the U.S. Jeuveau market while gaining share with Evolysse, showcasing strong positioning and growth potential in a competitive landscape.
- Future Outlook: Management reiterated the full-year revenue guidance of $327 million to $337 million and a low to mid-single-digit adjusted EBITDA margin, reflecting confidence in future growth, particularly with the upcoming Estyme launch and other pipeline milestones.
See More
Evolus Q1 Earnings Beat Expectations with Positive Outlook
- Strong Earnings Report: Evolus reported a Q1 GAAP EPS of -$0.16, beating expectations by $0.06, indicating an improvement in profitability that boosts market confidence in its future performance.
- Revenue Growth: The company achieved Q1 revenue of $73.1 million, a 6.7% year-over-year increase, surpassing market expectations by $0.93 million, demonstrating strong growth momentum in a competitive market.
- Positive Outlook: Evolus projects total net revenues for 2026 to be between $327 million and $337 million, reflecting a 10% to 13% growth over the previous year, showcasing the company's confidence in its strategic planning for future growth.
- Cost Management: The adjusted gross profit margin for 2026 is expected to be between 65.5% and 67.0%, with non-GAAP operating expenses projected between $210 million and $216 million, indicating effective cost control while maintaining operational efficiency.
See More
Conexeu Sciences Inc. Begins Trading on Nasdaq
- Listing Milestone: Conexeu Sciences Inc. commenced trading on Nasdaq on May 21, 2026, marking a significant advancement for the preclinical-stage company centered around its CXU™ bioregenerative platform, which is expected to attract more investment for product development.
- Innovative Platform: The CXU™ is a patented bioregenerative extracellular matrix designed to restore soft tissue lost due to injury, aging, and GLP-1-related weight loss, with its first product, Ten Minute Tissue™, demonstrating enhanced healing dynamics and a low inflammatory profile in preclinical studies, potentially garnering significant market interest.
- Market Outlook: Conexeu enters a public market that is showing genuine commercial momentum, with competitors like Integra LifeSciences and Bioventus exceeding expectations in recent earnings reports, indicating strong demand in the regenerative medicine sector, and the listing is likely to enhance Conexeu's market share.
- Strategic Positioning: The listing not only provides Conexeu with the opportunity for capital formation but also enables the advancement of the CXU™ platform across multiple product lines, with plans to submit a 510(k) application in early 2027, further solidifying its position in the regenerative medicine field.
See More
Conexeu Sciences Inc. Successfully Debuts on Nasdaq
- Listing Milestone: Conexeu Sciences Inc. commenced trading on Nasdaq on May 21, 2026, marking its entry into public markets as a regenerative tissue platform company, which is expected to drive business growth in wound care and aesthetic medicine sectors.
- Platform Advantage: The company's CXU™ extracellular matrix platform is designed to scale across multiple markets without reformulation, a structural advantage that sets it apart from early-stage regenerative medicine companies and may lay the groundwork for future market share expansion.
- Innovative Reconstruction Method: Conexeu's B.R.E.A.S.T.™ matrix is a 3D bioprinted scaffold designed to support the body's own tissue regeneration rather than serve as a permanent implant, representing a potential paradigm shift for over 100,000 U.S. women undergoing mastectomies annually.
- Intellectual Property Protection: Conexeu holds issued patents across the U.S., E.U., Japan, and Australia with no royalty or licensing obligations, providing the freedom to expand into new indications and potentially accelerating its 510(k) submission process.
See More
Evolus to Host Investor Meetings at Jefferies Conference
- Management Participation: Evolus's management team will participate in a fireside chat at the upcoming Jefferies Global Healthcare Conference on June 4, 2026, showcasing their expertise in aesthetics and likely attracting investor interest.
- Fireside Chat Timing: Scheduled for 12:50 PM ET, the chat will be accessible via the Investor Relations page on Evolus's website, enhancing interaction between the company and its investors.
- Webcast Replay Availability: A replay of the presentation will be available for 90 days post-event, ensuring that investors who cannot attend live can still access the information, thereby improving transparency and information dissemination.
- Company Background: Evolus is a global performance beauty company focused on redefining the aesthetic injectable market through its unique customer-centric business model and innovative digital platform, aiming to become a leader in the field.
See More
Evolus Launches Estyme® Injectable Products in Europe
- International Market Expansion: Evolus is set to commercially launch its Estyme® injectable hyaluronic acid gel collection on May 16, marking its entry into the international dermal filler market, which is expected to significantly enhance the company's market share in the global aesthetics sector.
- Product Diversity: The Estyme® collection includes Estyme®Smooth, Estyme®Form, Estyme®Lips, and Estyme®Sculpt, the latter of which is anticipated to receive FDA approval in the U.S., addressing the strong demand for mid-face volumizing treatments and enhancing the competitiveness of the company's product portfolio.
- Technological Innovation: Estyme®Sculpt utilizes Symatese's Cold-X® technology designed to preserve the natural structure of the hyaluronic acid molecule, providing long-lasting and natural-looking results, which will enhance practitioners' flexibility in treatments and patient satisfaction.
- Market Potential: The launch of Estyme® is expected to double Evolus's addressable market in the dermal filler category, supporting the company's strategic goal of becoming a global leader in multi-product aesthetics, thereby further solidifying its position in the industry.
See More
Evolus Q1 2026 Earnings Call Highlights
- Financial Performance: In Q1 2026, Evolus reported global net revenue of $73.1 million, including $66.4 million from Jeuveau and $6.7 million from Evolysse, indicating stable performance despite ongoing market challenges.
- Profitability Improvement: The company achieved positive adjusted EBITDA of $0.6 million in Q1, a significant turnaround from a loss of $5.5 million in the prior year, demonstrating progress in profitability and boosting investor confidence.
- Market Share Maintenance: Evolus maintained a 14% market share in the U.S. Jeuveau market while gaining share with Evolysse, showcasing strong positioning and growth potential in a competitive landscape.
- Future Outlook: Management reiterated the full-year revenue guidance of $327 million to $337 million and a low to mid-single-digit adjusted EBITDA margin, reflecting confidence in future growth, particularly with the upcoming Estyme launch and other pipeline milestones.
See More
Evolus Q1 Earnings Beat Expectations with Positive Outlook
- Strong Earnings Report: Evolus reported a Q1 GAAP EPS of -$0.16, beating expectations by $0.06, indicating an improvement in profitability that boosts market confidence in its future performance.
- Revenue Growth: The company achieved Q1 revenue of $73.1 million, a 6.7% year-over-year increase, surpassing market expectations by $0.93 million, demonstrating strong growth momentum in a competitive market.
- Positive Outlook: Evolus projects total net revenues for 2026 to be between $327 million and $337 million, reflecting a 10% to 13% growth over the previous year, showcasing the company's confidence in its strategic planning for future growth.
- Cost Management: The adjusted gross profit margin for 2026 is expected to be between 65.5% and 67.0%, with non-GAAP operating expenses projected between $210 million and $216 million, indicating effective cost control while maintaining operational efficiency.
See More
